Clinical trials: Hypobetalipoproteinemia
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Healthy
A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin
The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a…
- Trial name
- NCT01133366
- Testing
- warfarin sodium, mipomersen sodium; warfarin sodium
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
LDL - Low Density Lipoprotein Receptor Disorder, Rosuvastatin
Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels
Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels
- Trial name
- NCT06910098
- Testing
- Rosuvastatin
- Where
- Pakistan
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Central Park Medical College
Lipid Metabolism, Inborn Errors, Hyperlipidemias
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis.
- Conditions
- Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia
- Trial name
- NCT00362180
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Hypobetalipoproteinemia
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism
The aim of this study is to identify new targets in cholesterol metabolism thanks to a genetically-based strategy.
- Trial name
- HYPOCHOL (NCT02354079)
- Testing
- hypobetalipoproteinemia genetic and genotypic screening
- Where
- France
- Volunteers
- 435 people
- Sponsor
- Nantes University Hospital